NCT05303857Befejeződött4. fázis
Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
Randomized, Double-blind, Placebo Controlled, Parallel Group, Prospective Clinical Study to Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. jún. 11.
Rövid összefoglaló (regiszter, angolul)
This is a phase IV, randomized (1:1), prospective, double-blind, placebo controlled, parallel-group, single center study at the Clinical Research Unit (CRC) of the Department of Nephrology and Hypertension, with its two separate locations: * Nürnberg, Kreuzburger Str. 2, 90471 Nürnberg, and * Erlangen, Ulmenweg 18, 91054 Erlangen The main goal of the study is to demonstrate the effect of semaglutide on different vascular parameters of the macro- and microcirculation. The primary objective is to analyze the effect of semaglutide, compared to placebo on central (aortic) pulse pressure. At least 90 patients will be randomized (1:1) and included (informed consent, intention to treat population) in order to obtain 80 fully evaluable subjects (per protocol population). Patients will be simultaneously recruited from investigator's outpatient clinics, referring physicians, and advertisement in local newspapers, and social media. Those patients that appear to potentially fulfill the inclusion criteria will be invited to a screening visit (visit 1). After providing informed consent, patients will be tested for inclusion/exclusion criteria. Patients will provide a blood sample for laboratory testing. If the patient then fulfills inclusion criteria and in the absence of exclusion criteria, the patient will be enrolled into the trial, and the study visits will be scheduled. Randomization will take place at the latest one day prior to the study visit 2 (e.g. at the latest at visit 2a). At visit 2 (2a and 2b), baseline vascular function parameters will be obtained and the patient will be given a SC injection of the study drug (either SC 0.25 mg semaglutide or SC placebo). After giving detailed instructions to the patient how to apply the injections, the patient will be advised to apply the injection once weekly. A safety visit will be conducted 1 week after first administration of study drug (visit 3). At visit 4 and 5, semaglutide will be up-titrated to 0.5 mg and 1.0 mg respectively. At visit 6, a safety visit will be conducted and the dose of semaglutide will be kept at 1.0 mg. After 16 weeks of treatment (visits 7a and 7b), testing of vascular function will be repeated. At visit 7b, a final close out visit will be performed to gather additional safety information.
- Állapot (regiszter)
- Befejeződött
- Fázis (regiszter)
- 4. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 107 (tényleges)
- Első benyújtás
- 2022. márc. 14.
- Kezdés
- 2022. márc. 3.
- Elsődleges befejezés
- 2023. dec. 15.
- Fő szponzor
- University of Erlangen-Nürnberg Medical School
- Betegségek
- 2-es típusú cukorbetegség
- NCT-szám
- NCT05303857
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 4. fázis
- Bevont résztvevők: 107
- 2022. márc. 3. és az elsődleges befejezés (2023. dec. 15.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 3 months prior to study inclusion
- Drug or alcohol abuses
- Pregnant or breast-feeding patients
- Subset of patients receiving ASL-MRI, exclusion criteria-
- Patients with contraindications to MRI, including:
- Cochlear implant
Más betegség
- Any other form of diabetes mellitus than type 2 diabetes mellitus
- Uncontrolled arterial hypertension (BP ≥ 180/110 mmHg)
- Congestive heart failure (CHF) NYHA stage III and IV
- Implanted cardiac pacemaker or defibrillator, or presence of intracardiac wires
- Prosthetic heart valves
Laborértékek
- Patients with more than two oral blood glucose lowering medication
- HbA1c ≥ 10.5%
- Fasting plasma glucose > 240 mg/dl
- Estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m²
Egyéb
- Use of insulin, sulfonylurea or GLP-1 analogue within the past 3 months
- Body mass index > 40 kg/m²
- Any form of diabetic retinopathy, macular oedema
- Acute or chronic pancreatitis
- Brain aneurysm clip
- Implanted neural stimulator
- Ocular foreign bodies that might be ferromagnetic (e.g., metal shavings)
- Other implanted medical devices (e.g., insulin pumps)
- Metal shrapnel or bullets still in the body
- Severe claustrophobia
- Tattoos (as determined by the Investigator and Imager)
- Weight in excess of MRI machine capacity
Kiket keres a vizsgálat
- Age of 18 - 75 years
- Diagnosis of type 2 diabetes mellitus: defined by fasting glucose ≥ 126 mg/dl or HbA1c ≥ 6,5 % or on oral single or dual blood glucose lowering medication (held constant for the last 3 months)
- HbA1c ≥ 7.0%
- Male and Female patients (females of child bearing potential must be using adequate contraceptive precautions)
- Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit
- Informed consent (§ 40 Abs. 1 Satz 3 Punkt 3 AMG) has to be given in written form
Életkor a regiszterben: 18 év – 75 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Clinical Research Center, Department of Nephrology and Hypertension, University Hospital Erlangen | Erlangen | Németország | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.